Relapse remains the most important cause of failure for many patients undergoing either autologous or allogeneictransplant for the treatment of malignant lymphoma and acute myelogenous leukemia. This project will focus on studiesof radioimmunotherapy targeted to tumor-associated antigens, as a component of the preparatory regimens forautologous and allogeneic hematopoietic cell transplantation used in the treatment of these diseases. The proposedstudies seek to improve the anti-tumor efficacy, as well as reduce the toxicity of the procedure which will extend theapplication of hematopoietic cell transplantation (HCT) to older patients who form the majority of patients with both AMLand lymphoma. The proposed studies will investigate the incorporation of radiolabeled antibodies conjugated to aheavy metal radioisotope (Yttrium-90) that target either the CD20 antigen on malignant B-cells or the CD33 antigen onblasts in patients with AML and myelodysplasia. We propose to perform five clinical studies using novel regimens forautologous or allogeneic transplant for AML and B-cell lymphoma: 1) For patients with advanced lymphoma (low-grade,intermediate-grade, and mantle cell) we will continue our studies of high-dose 90Y-labeled anti-CD20 antibody combinedwith etoposide and cyclophosphamide in the Phase II setting; 2) For older patients (age>60) with relapsed lymphomawe will extend our Phase I observations to a Phase II study of 90Y-labeled anti-CD20 antibody combined with BEAMchemotherapy in order to develop an effective regimen that can be used safely in this population of patients;3) 90Y-labeled anti-CD20 antibody will also be developed as part of a reduced intensity allogeneic transplant regimen for patients with lymphoma who are not candidates for an autologous approach, including those with relapsed mantle cell lymphoma, multiple relapsed low-grade lymphoma, or patients who have relapsed after autologous transplant; 4) For patients with AML, who have intermediate- and high-risk cytogenetics, we will initiate a study of 90Y-labeled anti-CD33 antibody to replace total body irradiation in combination with etoposide and cyclophosphamide for autologoustransplant; 5) After completion of a Phase I safety study, we will conduct a Phase II study with this regimen. Forpatients with advanced leukemia (early relapse, older age, AML with prior MDS, relapse after auto-transplant), we willincorporate the 90Y-labeled anti-CD33 antibody into a reduced intensity allogeneic transplant regimen to improve theoutcome for this high-risk population of patients. It is the general hypothesis of this project that targeted radiationtherapy as a component of the autologous and allogeneic transplant preparative regimens will help improve therapeuticefficacy by decreasing post-HCT disease relapse and by reducing toxicity, thereby extending the potential benefit oftreatment to a larger population of patients with these diseases.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-2 (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications